Akebia Therapeutics (NASDAQ: AKBA) has announced the publication of a post-hoc win statistics analysis of all-cause mortality and hospitalization from its global Phase 3 INNO2VATE program in the peer-reviewed Journal of the American Society of Nephrology (JASN).
The research letter titled “Comparing Vadadustat and Darbepoetin in Maintenance Dialysis with Chronic Kidney Disease-Related Anemia” found that vadadustat showed a statistically significant improvement over the erythropoiesis-stimulating agent darbepoetin alfa on a composite endpoint of all-cause mortality and hospitalization in dialysis patients with CKD-related anemia.
In a statement, Dr. Steven Burke, chief R&D and medical officer at Akebia, commented, “The win statistics analysis highlighted favorable outcomes and potential clinical differentiation for Vafseo that we believe are central to ensure informed clinical decision-making for nephrologists and other care providers. As we work toward our goal to make Vafseo standard of care in patients with anemia due to CKD receiving dialysis, we believe publication in JASN further validates the strength of the vadadustat dataset and supports strong engagement with prescribers, providers and payors.”
